VTE Prevention in the Hospitalized Medical Patient

Eric Howell, MD, MHM

Scott Kaatz, DO, MSc, SFHM

Steve Deitelzweig, MD, SFHM

Paul Grant, MD

Summary

The world of anticoagulation management is complex. Pharmaceutical breakthroughs in the last few years have created a myriad of questions and protocols for practitioners to consider. In this changing landscape rapid changes create a gap between current and optimal care and professional education is key for bridging that gap.

In an October 2016 survey of 45 SHM chapter leaders, 51 percent of respondents selected “VTE and Anticoagulation Updates” as a top priority, ranking it the sixth-most important topic out of nineteen available options.

Goal

Provide timely, relevant education centered on key issues of VTE prevention in the hospitalized medically ill (non-surgical) patient.

Target Audience

This activity is designed for hospitalists, nurse practitioners, and physician assistants.

Learning Objectives

After completing the module, the participant will demonstrate the ability to:

  1. Appreciate the American College of Physicians (ACCP) guidelines to perform venous thromboembolism (VTE) risk assessment in hospitalized medical ill patients.
  2. Know how to apply VTE risk assessment models to aid in identifying at risk patients
  3. Identify patients at-risk for VTE and determine the appropriate prophylactic approach at the time of admission and throughout hospitalization.
  4. Be able to identify patients that do not need VTE prophylaxis
  5. Appreciate the risk and benefit of extended VTE prophylaxis after hospital discharge and identify appropriate patients
Accreditation Statement 

The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Statement Designation

The Society of Hospital Medicine designates this activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Release Date: 9/15/2018  Expiration Date: 9/15/2020

Conflict of Interest Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, SHM requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. SHM resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. All relevant financial relationships shall be disclosed to participants prior to the start of the activity.

Furthermore, SHM seeks to verify that all scientific research referred to, reported, or used in a continuing medical education (CME) activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SHM is committed to providing its learners with high-quality CME activities that promote improvements in healthcare and not those of a commercial interest.

Instructions

The following is an interactive educational module designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of several sections: a pre-test, a study program, a post-test, & CME evaluation. All sections must be completed to receive CME credit.

Course summary
Course opens: 
09/04/2018
Course expires: 
09/15/2020
Your cost:
$0.00
Rating: 
0

Eric Howell, MD, MHM

Dr. Howell reports having no relevant financial or advisory relationships with corporate organizations relevant to this activity.

Scott Kaatz, DO, MSc, SFHM

Dr. Kaatz has disclosed the following conflicts relevant to this activity:

  • Consulting for Pfizer
  • Advisory Committee/Board for Janssen, Bristol Myer Squibb, Pfizer, Portola, and Roche
  • Research Grants/Contracts from Janssen

Steve Deitelzweig, MD, SFHM

Dr. Deitelzweig has disclosed the following conflicts relevant to this activity:

  • Consulting for Pfizer, Portola, BMS
  • Advisory Committee/Board for Pfizer and Daiichi Sankyo
  • Speakers Bureau, Faculty , or Peer Reviewer for Pfizer, BMS, and Portola

Paul Grant, MD

Dr. Grant reports having no relevant financial or advisory relationships with corporate organizations relevant to this activity.

Planning staff associated with the development of this activity have no relevant conflicts to report.

SHM Conflict of Interest Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, SHM requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. SHM resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. All relevant financial relationships shall be disclosed to participants prior to the start of the activity.

Furthermore, SHM seeks to verify that all scientific research referred to, reported, or used in a continuing medical education (CME) activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SHM is committed to providing its learners with high-quality CME activities that promote improvements in healthcare and not those of a commercial interest.

Available Credit

Accreditation Period

Course opens: 
09/04/2018
Course expires: 
09/15/2020

Price

Your cost:
$0.00
Please login or register to take this course.